<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04098445</url>
  </required_header>
  <id_info>
    <org_study_id>2019-0001C</org_study_id>
    <nct_id>NCT04098445</nct_id>
  </id_info>
  <brief_title>TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients</brief_title>
  <official_title>TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hematopoietic stem cell transplant (HSCT) is an effective but toxic therapy and pulmonary&#xD;
      morbidity affects as many as 25% of children receiving transplant. Early pulmonary injury&#xD;
      includes diffuse alveolar hemorrhage (DAH), thrombotic microangiopathy (TMA) interstitial&#xD;
      pneumonitis (IPS) and infection, while later, bronchiolitis obliterans is a complication of&#xD;
      chronic GVHD associated with severe morbidity and mortality. Improved diagnosis and treatment&#xD;
      of pulmonary complications are urgently needed as survival after HSCT improves, and as HSCT&#xD;
      is increasingly used for non-malignant disorders such as sickle cell disease. Currently,&#xD;
      there are large and important gaps in the investigator's knowledge regarding incidence,&#xD;
      etiology and optimal treatment of pulmonary complications. Moreover, young children unable to&#xD;
      perform spirometry are often diagnosed late, and strategies for monitoring therapeutic&#xD;
      response are limited.&#xD;
&#xD;
      This is a prospective multi-institutional cohort study in pediatric patients undergoing&#xD;
      allogeneic (alloHSCT) or autologous hematopoietic stem cell transplantation (autoHSCT).&#xD;
      Assembly of a large prospective uniformly screened cohort of children receiving HSCT,&#xD;
      together with collection of biological samples, will be an effective strategy to identify&#xD;
      mechanisms of lung injury, test novel diagnostic strategies for earlier diagnosis, and novel&#xD;
      treatments to reduce morbidity and mortality from lung injury after transplant.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 8, 2021</start_date>
  <completion_date type="Anticipated">September 2036</completion_date>
  <primary_completion_date type="Anticipated">September 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Lung Injury after HSCT</measure>
    <time_frame>24 months after HSCT</time_frame>
    <description>Participants will be assessed for lung injury at 24 months after HSCT</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Hematopoietic Stem Cell Transplant (HSCT)</condition>
  <condition>Diffuse Alveolar Hemorrhage</condition>
  <condition>Thrombotic Microangiopathies</condition>
  <condition>Interstitial Pneumonitis</condition>
  <condition>Bronchiolitis Obliterans</condition>
  <arm_group>
    <arm_group_label>Pediatric and young adult HSCT recipients</arm_group_label>
    <description>Prospective multi-institutional cohort study in pediatric patients undergoing allogeneic (alloHSCT) or autologous hematopoietic stem cell transplantation (autoHSCT).</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The study participants will include eligible patients undergoing allogeneic or autologous&#xD;
        HSCT at participating institutions.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects â‰¤ 24 years of age undergoing allogeneic or autologous HSCT.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects over 24 years of age.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>24 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stella Davies, MBBS, PhD, MRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephanie Edwards, BSN, RN</last_name>
    <phone>513-636-9292</phone>
    <email>StephanieL.Edwards@cchmc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sara Loveless, BSN, RN</last_name>
    <phone>513-803-7656</phone>
    <email>Sara.Loveless@cchmc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Loveless, BSN, RN</last_name>
      <phone>513-803-7656</phone>
      <email>Sara.Loveless@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Stella Davies, MBBS, PhD, MRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jason Woods, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 19, 2019</study_first_submitted>
  <study_first_submitted_qc>September 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2019</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiolitis</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Lung Injury</mesh_term>
    <mesh_term>Bronchiolitis Obliterans</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
    <mesh_term>Thrombotic Microangiopathies</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

